Abbott announced that the Food and Drug Administration (FDA) has approved FreeStyle Libre Pro system, a new continuous glucose monitoring (CGM) system for healthcare professional use. 

The new CGM system provides healthcare professionals with a patient’s ambulatory glucose profile (AGP), showing a clearer overview of glucose levels, patterns, and trends. The AGP helps detect when the patient is out of glucose range and provides hypoglycemic and hyperglycemic trends. 

Related Articles

The FreeStyle Libre Pro system is a small, round sensor that is applied by healthcare professionals to the back of the patient’s upper arm. The sensor is held in place with a self-adhesive pad for up to 14 days. Patient interaction with the device or a blood draw via a fingerstick to calibrate the device are not needed. A small filament that is inserted just under the skin continuously measures glucose in interstitial fluid. It can capture up to 1,340 results for up to 14 days, as it records glucose levels every 15 minutes. At the end of 14 days, the clinician uses a FreeStyle Libre Pro reader to scan the sensor and download the 14-days’ worth of glucose results in 5 seconds. 

The FreeStyle Libre Pro is water-resistant in up to 3 feet of water and is disposable. The consumer version of the FreeStyle Libre system has been submitted to the FDA for review.

For more information call (847) 937-6100 or visit